Programmed Cell-Derived Vesicles for Targeted Macrophage Repolarization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cell-derived vesicle therapies face challenges such as low production yields, lack of targeting specificity, and immunomodulatory potency, leading to off-target effects and systemic immune activation, while synthetic nanoparticles suffer from rapid degradation and toxicity.
Innovation Solution
Programmed cell-derived vesicles (CDVs) are generated by fragmenting cellular membranes of donor cells that overexpress specific ligands, such as CD54, TNF-α, or CpG-ODN, and are isolated from organelles like the endoplasmic reticulum, allowing for targeted and immunomodulatory properties to repolarize macrophages from an M2 to an M1 phenotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exosomes are used for targeted therapeutic delivery, then targeting specificity and biocompatibility are improved, but production yield is low and separation from biological solutions is difficult
Solution Approach 1:
The patent uses cell-derived vesicles (CDVs) as a copy or alternative to exosomes, replicating their targeting specificity and biocompatibility while achieving higher production yields through scalable cell culture methods
Solution Approach 2:
The patent modifies the production parameters by using different cell types (e.g., macrophages, dendritic cells) and culture conditions to optimize CDV production yield while maintaining the therapeutic functionality similar to exosomes
2Productivity
If liposomes are used for therapeutic delivery, then production quantity is improved, but biocompatibility is reduced and immune clearance occurs
Solution Approach 1:
The patent creates a composite approach by using cell-derived membranes that naturally combine biocompatible lipids and proteins, achieving both high production quantities and superior biocompatibility compared to synthetic liposomes
Solution Approach 2:
The patent uses readily available cell lines that can be rapidly cultured and differentiated to produce large quantities of CDVs, making the production process more accessible and scalable than synthetic alternatives
3Productivity
If conventional cell-derived vesicles are used, then high production yield is achieved, but targeting specificity and immunomodulatory potency are insufficient
Solution Approach 1:
The patent applies local quality by differentiating specific cell types (e.g., M1 macrophages, dendritic cells) to express particular surface markers and cytokines that provide targeted immunomodulatory functions to specific tissue locations
Solution Approach 2:
The patent performs preliminary action by pre-differentiating cells to desired phenotypes (e.g., polarizing macrophages to M1 or M2 states) before vesicle formation, ensuring the CDVs are pre-programmed with specific targeting and immunomodulatory capabilities
4Adaptability or versatility
If M2 macrophages are present in tumor microenvironment, then tumor angiogenesis is stimulated, but anti-tumor immune response is inhibited
Solution Approach 1:
The patent applies inversion by using M1-polarized CDVs to reverse the phenotype of M2 macrophages in the tumor microenvironment, converting them from immunosuppressive to immunostimulatory cells, thereby enhancing anti-tumor immunity
Solution Approach 2:
The patent uses CDVs as intermediary carriers of polarizing factors (e.g., cytokines like IFN-γ, LPS) that mediate the phenotype转换 of macrophages from M2 to M1 state, enabling controlled immunomodulation in the tumor microenvironment
Data Source
AI summary
The presently-disclosed subject matter includes programmed cell-derived vesicles (CDVs), methods of making programmed CDVs, and methods of using programmed CDVs.